Get the Stockscreener App
16.25
5.11%
0.79
After Hours:
15.00
-1.25
-7.69%
Cvrx Inc stock is traded at $16.25, with a volume of 260.40K.
It is up +5.11% in the last 24 hours and up +19.13% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$15.46
Open:
$15.29
24h Volume:
260.40K
Relative Volume:
0.99
Market Cap:
$394.28M
Revenue:
$47.26M
Net Income/Loss:
$-58.48M
P/E Ratio:
-6.0076
EPS:
-2.7049
Net Cash Flow:
$-40.45M
1W Performance:
-6.18%
1M Performance:
+19.13%
6M Performance:
+97.45%
1Y Performance:
-33.46%
1-Day Range:
$15.29
$16.59
1-Week Range:
$15.29
$17.78
52-Week Range:
$6.40
$25.04
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
16.25 | 394.28M | 47.26M | -58.48M | -40.45M | -2.7049 |
|
ABT
Abbott Laboratories
|
129.10 | 223.92B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
103.54 | 152.60B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
392.39 | 149.59B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.97 | 116.65B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.33 | 42.07B | 6.60B | 4.16B | 490.10M | 6.93 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CVRx Announces Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: CVRx Q4 2024 shows revenue growth, stock dips - Investing.com
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Canada Finance
CVRx: Q4 Earnings Snapshot - Leader-Telegram
Earnings Flash (CVRX) CVRX INC. Reports Q4 Revenue $15.3M, vs. FactSet Est of $15.1M - Marketscreener.com
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - The Bakersfield Californian
CVRx Earnings Showcase: Heart Failure Treatment Propels 41% Revenue Explosion in Core Market - StockTitan
CVRx, Inc. (NASDAQ:CVRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
CVRx Inc (CVRX) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
(CVRX) Technical Data - Stock Traders Daily
William Blair upgrades CVRx on stabilization of business - MSN
CVRx Inc (CVRX) Shares Down 4.32% on Jan 24 - GuruFocus.com
Analysts Issue Forecasts for CVRx FY2025 Earnings - Defense World
CVRx, Inc. (NASDAQ:CVRX) Stock Holdings Increased by Barclays PLC - Defense World
Analysts Set Expectations for CVRx FY2025 Earnings - MarketBeat
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025 - GlobeNewswire
CVRx to Report Q4 2024 Financial Results for Barostim Device on February 4 - StockTitan
CVRx stock price target increased, buy rating on growth acceleration - MSN
CVRx (NASDAQ:CVRX) Reports Strong Financial Results for Q4 and Fiscal Year 2024; Issues 2025 Guidance - Defense World
Craig Hallum Forecasts Strong Price Appreciation for CVRx (NASDAQ:CVRX) Stock - Defense World
Craig Hallum Issues Positive Forecast for CVRx (NASDAQ:CVRX) Stock Price - MarketBeat
Where CVRx Stands With Analysts - Benzinga
CVRx stock price target increased, buy rating on growth acceleration By Investing.com - Investing.com Australia
CVRx (NASDAQ:CVRX) Upgraded at William Blair - Defense World
William Blair Has Bullish Estimate for CVRx FY2024 Earnings - Defense World
CVRx says total Q4 revenue is expected to be between $15.2M and $15.3M - MSN
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Equities Analysts Set Expectations for CVRx FY2024 Earnings - MarketBeat
CVRx (CVRX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 27% - Simply Wall St
CVRx (CVRX) to Release Earnings on Thursday - Defense World
CVRx upgraded by William Blair to outperform - MSN
(CVRX) On The My Stocks Page - Stock Traders Daily
| MarketBeat - MarketBeat
Jane Street Group LLC Acquires 5,053 Shares of CVRx, Inc. (NASDAQ:CVRX) - Defense World
CVRx projects robust revenue growth for Q4 and full year 2024 - Investing.com India
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance - The Manila Times
CVRx Reports Strong Q4 Growth: Revenue Surges 35% as Heart Failure Treatment Demand Accelerates - StockTitan
Barclays PLC Purchases 14,445 Shares of CVRx, Inc. (NASDAQ:CVRX) - Defense World
Geode Capital Management LLC Grows Position in CVRx, Inc. (NASDAQ:CVRX) - Defense World
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):